Research notes

SYL’s recent investor day left us with the impression that the pipeline of potential work is immense, as the business progresses its $7.5bn of recently tendered work, along with a further $1.4bn of projects in early contractor involvement (‘ECI’). Across the key verticals of infrastructure, digital, energy and defence, the total addressable market continues to grow, which along with M&A, could see the business delivering early on its FY30 aspirational EBITDA target of $200m. Given SYL’s history of winning approximately one out of four tenders and no sign of Government investment budgets abating, the investment thesis for SYL as the ‘picks and shovels’ of the infrastructure build out remains intact. On this basis, we reaffirm our Buy rating and $3.35/sh price target.

VISA is a global payments technology company that enables fast, secure and reliable electronic payments across more than 200 countries and territories. It facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities

The Home Depot is the world’s largest home improvement retailer with operations in the US and internationally. It sells various building materials, home improvement products, lawn and garden products, and décor products, as well as facilities maintenance, repair, and operations products.

WES’s share price has fallen 9% over the past 12 months and 7% over the past 6 months. The stock is now trading on a more reasonable 26.5x FY27F PE compared to a peak one-year forward multiple of ~37x in August 2025. We adjust FY26/27/28F group EBIT by +0%/+2%/+2%, primarily reflecting higher lithium earnings driven by updated price assumptions. Our target price increases slightly to $81.10 (from $80.50) and with a forecast 12-month TSR of 12%, we upgrade our rating to ACCUMULATE (from TRIM). In our view, WES remains a high-quality business with a healthy balance sheet and a proven management team. Amid ongoing geopolitical uncertainty and cost-of-living pressures, its retail divisions (Bunnings, Kmart Group, Officeworks, Priceline) are well-placed to grow due to their strong value propositions. A sustained improvement in lithium prices should also support earnings over the medium term.

GYG announced the immediate exit of its US operations, a business that we forecast generated a significant FY26 underlying EBITDA loss and required materially more capital than could be justified by prospective returns. We view this as a positive catalyst, notwithstanding that the market has previously ascribed meaningful optionality value to the US as a long-term growth engine. The exit removes a loss sooner than consensus anticipated and simplifies the story while the Australian operations are performing well and in line with expectations. Stripping out the US losses results in material upgrades to our EBITDA and NPAT forecasts. We maintain our BUY rating and upgrade our price target to A$29.40.

CAT’s FY26 result confirmed strong organic momentum, with revenue US$141m (+19% c/c) and closing ACV US$134m (+28% c/c) at the top of guidance, while Management EBITDA of US$25m (17.6% margin, +67% pcp) beat MorgansF. Operating leverage is now evident, with a 41% incremental margin (48% ex-acquisitions) in the period. ACV per pro team crossed US$30k for the first time whilst SaaS metrics improved. We trim FY27-FY29F Management EBITDA by 6-8% factoring in the result. Our price target is lowered to A$5.40 (from A$5.55) on these changes, offset to a degree by a valuation roll forward. BUY maintained.

VFY has released final Phase II in-vitro platelet results from USAISR, with all three cryopreservation protocols exceeding fresh-platelet quality benchmarks. The headline result was 94% post-thaw recovery using the 3% DMSO no-wash protocol, well ahead of the FDA/AABB (~75%) and European (~50%) thresholds. The study is independently authored by the US Army across 20 donors and 60+ samples at commercial volumes, delivering on a core IPO commitment made at listing in November 2024. No FDA-approved no-wash frozen platelet product exists commercially in the US, positioning Vitrafy to address a genuine category gap. Shares trading up strongly from the $1.20 YTD lows, and +27% on the 2024 IPO price.

Strong 1H26 results continue into 3Q26 which continued to deliver record sales contracts and revenue already exceeding FY25's full-year result, signaling strong near-term momentum. CNS market growth, expanding operating leverage with Medidata partnership and AI Investment underpin expectations for a multi-year growth outlook.

NEU delivered a strong first half, underpinned by continued growth in royalties to A$65m, a large cash position and continued operational momentum with record DAYBUE® patient uptake in the US and progress toward global expansion. NEU is recruiting for its Phase 3 clinical trial for Phelan-McDermid Syndrome (PMS) and expects recruitment to complete in late CY27. If there is clinical success, management expects this will be a major-value creation point. The consensus (Factset) target price is A$23.74 versus the current share price of A$12.42.